Skip to main content
Noile-Immune Biotech Inc. logo

Noile-Immune Biotech Inc. — Investor Relations & Filings

Ticker · 4893 ISIN · JP3759560000 T Manufacturing
Open in API
Filings indexed 25 across all filing types
Latest filing 2026-03-23 Regulatory Filings
Country JP Japan
Listing T 4893

About Noile-Immune Biotech Inc.

https://www.noile-immune.com/en.html

Noile-Immune Biotech Inc. is a clinical-stage biotechnology company focused on the development and commercialization of novel cancer immunotherapies. The company specializes in next-generation Chimeric Antigen Receptor T-cell (CAR-T) therapies, leveraging its proprietary PRIME (Proliferation-Inducing and Migration-Enhancing) technology. This platform is designed to enhance the efficacy of CAR-T cells by enabling them to produce specific cytokines and chemokines, thereby improving their proliferation, persistence, and ability to infiltrate the tumor microenvironment. A primary goal is to develop effective treatments for solid tumors, a significant challenge for conventional cell therapies. The company advances its pipeline through internal research and development as well as strategic partnerships.

Recent filings

Filing Released Lang Actions
確認書
Regulatory Filings Classification · 1% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act, Article 24-4-2, Paragraph 1. It serves as an officer certification confirming the accuracy of the company's Annual Securities Report (有価証券報告書). According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations, even if they reference a specific report, should be classified as Regulatory Filings (RNS). FY 11
2026-03-23 Japanese
有価証券報告書－第11期(2025/01/01－2025/12/31)
Annual Report Classification · 1% confidence The document is a 'Yuka Shoken Hokokusho' (Annual Securities Report) filed with the Kanto Local Finance Bureau in Japan. It covers the fiscal year from January 1, 2025, to December 31, 2025, and includes detailed financial statements, business descriptions, and management information. This document is the Japanese equivalent of a 10-K filing. FY 2025
2026-03-23 Japanese
確認書
Report Publication Announcement Classification · 1% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under Article 24-5-2 of the Financial Instruments and Exchange Act of Japan, which accompanies a semi-annual/quarterly report. While it references the 'Second Quarter Report' (第２四半期報告書), the document itself is a regulatory confirmation statement required by Japanese law to accompany the filing. Since it is a specific regulatory filing required for the submission of financial reports and does not fit into the primary report categories, it is classified as a Regulatory Filing (RNS).
2025-08-08 Japanese
半期報告書－第11期(2025/01/01－2025/12/31)
Interim / Quarterly Report Classification · 1% confidence The document is a '半期報告書' (Semi-annual Report) for Noile-Immune Biotech Inc., covering the period from January 1, 2025, to June 30, 2025. It contains detailed financial statements, including the balance sheet, income statement, and cash flow statement, as well as management analysis and notes. This fits the definition of an Interim/Quarterly Report (IR) as it provides comprehensive financial data for a period shorter than a full fiscal year. H1 2025
2025-08-08 Japanese
臨時報告書
AGM Information Classification · 1% confidence The document is titled "臨時報告書" (Extraordinary Report) and explicitly states in Section 1 that it is being filed pursuant to Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act because resolutions were passed at the company's 10th Annual General Meeting (定時株主総会) held on March 26, 2025. Section 2 details the resolutions passed, including the election of directors and approval of a restricted stock compensation plan. This document reports the *results* of a shareholder meeting, not the solicitation materials (PSI) or the meeting presentation itself (AGM-R). The most specific category for reporting official results from a shareholder vote is 'Declaration of Voting Results & Voting Rights Announcements' (DVA).
2025-04-01 Japanese
確認書
Audit Report / Information Classification · 1% confidence The document text contains Japanese characters and includes the header "有価証券報告書（通常方式）" which translates to 'Securities Report (Normal Method)'. It explicitly mentions the '金融商品取引法' (Financial Instruments and Exchange Act) and confirms the appropriateness of the '有価証券報告書' (Securities Report) for the fiscal period ending December 31, 2024. A comprehensive Securities Report filed under Japanese regulations is equivalent to the US 10-K filing, which covers full yearly financial performance and company activity. Although the document itself appears to be a confirmation statement ('確認書') related to the filing, the core subject matter is the annual Securities Report (10-K equivalent). Given the options, '10-K' is the closest classification for a comprehensive annual report document, even if this specific snippet is a confirmation attached to it, as it directly references the annual filing content. FY 2024
2025-03-28 Japanese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.